PROM1 and acute myeloid leukemia: Besides FLYSYN, we also conceptualized an Fc-optimized mAb targeting the pentaspan transmembrane glycoprotein CD133 (prominin-1), which showed superior induction of NK cell reactivity in AML and in colorectal cancer (CRC) [19,20].